Literature DB >> 31842557

Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.

Kristýna Pivovarčíková, Petr Martínek, Kiril Trpkov, Reza Alaghehbandan, Cristina Magi-Galluzzi, Enric Condom Mundo, Daniel Berney, Saul Suster, Anthony Gill, Boris Rychlý, Květoslava Michalová, Tomáš Pitra, Milan Hora, Michal Michal, Ondřej Hes.   

Abstract

Hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma (HLRCC)/ fumarate hydratase deficient renal cell carcinoma (FHRCC) is an aggressive tumor defined by molecular genetic changes - alteration in fumarate hydratase (FH) gene. The morphologic spectrum of HLRCC/FHDRCC is remarkably variable. The presence of large nuclei and prominent dark red inclusion-like nucleoli and perinucleolar clearing are considered as helpful morphologic clue. We selected 23 renal neoplasms primarily based on their morphologic features suspicious for HLRCC/FHDRCC. Morphological, basic immunohistochemical, and genetic analysis was performed. The tumors were divided in two groups according to the molecular genetic findings. The first group included 13 tumors with detected FH mutation/LOH (compatible with diagnosis FHRCC), and the second group included 10 tumors without FH mutation/LOH (FH-like RCCs). In the FHRCC group, the vast majority of cases (9/13) had mixed morphology with different architectural growth patterns. All cases showed prominent macronucleoli, and perinucleolar clearing was found in 10/13 cases. Immunohistochemically, 6/7 FHRCC cases were negative for FH antibody, while one case showed strong diffuse FH reactivity. The FH-like RCC group showed more uniform architectural growth pattern. All 10 tumors had prominent macronucleoli, and perinucleolar clearing was present in 8/10 cases. Eight FH-like RCC cases showed diffuse strong positivity for FH, although 2 cases were completely negative for FH. It is evident that neither morphologic feature nor immunohistochemical analysis can be reliably used in routine practice for the diagnosis of HLRCC/FHRCC. In suspected cases, the diagnosis of HLRCC/FHRCC can be confirmed by molecular-genetic testing for FH mutation. It should be noted that the traditionally described morphologic features of HLRCC/FHRCC (prominent eosinophilic macronuclei with perinucleolar halos) can frequently be seen in other renal neoplasms.

Entities:  

Keywords:  HLRCC; fumarate hydratase; renal cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31842557

Source DB:  PubMed          Journal:  Cesk Patol        ISSN: 1210-7875


  2 in total

1.  Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity.

Authors:  Khaleel I Al-Obaidy; Rola M Saleeb; Kiril Trpkov; Sean R Williamson; Ankur R Sangoi; Mehdi Nassiri; Ondrej Hes; Rodolfo Montironi; Alessia Cimadamore; Andres M Acosta; Zainab I Alruwaii; Ahmad Alkashash; Oudai Hassan; Nilesh Gupta; Adeboye O Osunkoya; Joyashree D Sen; Lee Ann Baldrige; Wael A Sakr; Muhammad T Idrees; John N Eble; David J Grignon; Liang Cheng
Journal:  Mod Pathol       Date:  2022-02-12       Impact factor: 8.209

Review 2.  [FH-deficient renal cell carcinoma expands the spectrum of renal papillary tumors].

Authors:  N Rupp; H Moch
Journal:  Pathologe       Date:  2021-08-27       Impact factor: 1.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.